Evaluation of the clinical efficiencyof lokivetmab in client privately ownedatopic dogs – multicenter study

Atopic dermatitis (AD) is the most frequent allergic disease in dogs. AD can be treated using allergenspecific immunotherapy as well symptomatic antipruritic treatment including use of lokivetmab - caninized anti-interleukine-31 antibody.The aim study was to evaluate effectiveness over 12 weeks treat-ment. Studies have been carried out 89 In all affected animals, severity lesions assessed CADESI 04 and pruritus VAS.After first dose lokivetmab, both VAS statistical decreased by 4 from 40.48 20.31, 7.42 2.48, respectively (p = 0.0000001) maintained significantly decresed values during whole period (CADESI 15.64, 15.07 after 8 weeks, respectively, PVAS 2.03, 1.95 respectively).Lokivetmab leads a significant reduction pruritus, within four maximum effect achived second dose.